In order to differentiate prognosis and direct treatment, the molecular classification of BC is based on immunohistochemistry (IHC) subtypes such as the expression status of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), and as a result, its pathological characteristics and treatment vary significantly [3]. Here, ERBB2 is linked to breast cancer.